IP Library Granted Patent US 12,404,513
Granted Patent B2
US 12,404,513 · App. 18/504,952 · Granted Sep 2, 2025

Single-vector Type I vectors

Inventors: Virginia Martinez (Copenhagen Ø, DK); Ruben Vazquez-Uribe (Copenhagen Ø, DK); Adam Takos (Copenhagen Ø, DK); Eric Van Der Helm (Copenhagen Ø, DK)
Assignee: SNIPR BIOME APS
C12N15/70A61K31/7088A61K38/465A61P3/04A61P31/04C07K14/33C12N9/22C12N15/11C12N2310/20C12N2800/80C12N2820/002C12N2820/007C12N2820/55C12N2830/005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,513
App. No.
18/504,952
Granted
Sep 2, 2025
Kind
B2
Abstract

The invention relates to the production and use of Cas-encoding sequences and vectors comprising these. Aspects of the invention provide products, vectors, delivery vehicles, uses and methods for producing Cas-encoding sequences in bacterial or archaeal cells.

Claims (55)

1. A production strain bacterial cell comprising a nucleic acid vector for introduction into a target bacterial host cell for expression of Type I Cas3 and Cascade proteins in the target bacterial host cell, the vector comprising a first nucleotide sequence encoding a Type I Cas3 and a second nucleotide sequence encoding one or more cognate Cascade proteins, wherein the first nucleotide sequence is under the control of a promoter for controlling the expression of Type I Cas3 in the target bacterial host cell, wherein the promoter has a strength that is weaker than the Anderson Score strength of promoter BBa_J23108,

wherein the nucleic acid vector further comprises: (i) a CRISPR array for producing a crRNA in the target bacterial host cell; or (ii) a nucleotide sequence encoding a guide RNA (gRNA), wherein the crRNA or gRNA comprises a spacer sequence complementary to a target sequence of the target bacterial host cell, and

wherein the production strain bacterial cell does not comprise a crRNA or gRNA operable with the Cas3 to target and cut a chromosomal sequence of the production strain cell.

2. The production strain bacterial cell of claim 1 , wherein the target bacterial host cell is selected from the group consisting of Campylobacter, Burkholderia , and Acinetobacter.

3. The production strain bacterial cell of claim 2 , wherein the promoter is operable in a target host cell selected from the group consisting of Campylobacter jejuni, Campylobacter coli, Campylobacter lari, Burkholderia cepacia, Burkholderia cenocepacia, Burkholderia multivorans, Burkholderia vietnamiensis, Burkholderia stabilis, Burkholderia thailandensis, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Acinetobacter lwoffi , and Acinetobacter schindleri.

4. The production strain bacterial cell of claim 3 , wherein the Type I Cas3 and Cascade are E. coli, C. difficile, P. aeruginosa, K. pneumoniae, P. furiosus , or B. halodurans Cas and Cascade proteins.

5. The production strain bacterial cell of claim 1 , wherein the nucleic acid vector comprises an operon for expression of the Type I Cas3 and Cascade proteins, and:

(a) the first nucleotide sequence is between the promoter and the second nucleotide sequence in the operon;

(b) the operon comprises no Cas-encoding nucleotide sequences between the promoter and the first nucleotide sequence; or

(c) the operon comprises, in 5′ to 3′ direction, the promoter, the first nucleotide sequence, and the second nucleotide sequence.

6. The production strain bacterial cell of claim 1 , wherein the promoter is a constitutive promoter.

7. The production strain bacterial cell of claim 1 , wherein the promoter is repressible.

8. The production strain bacterial cell of claim 1 , wherein the promoter has a strength that is greater than the Anderson Score strength of promoter BBa_J23114.

9. The production strain bacterial cell of claim 1 , wherein the nucleic acid vector further comprises an origin of replication that is operable in the target bacterial host cell.

10. The production strain bacterial cell of claim 1 , wherein the nucleic acid vector is devoid of a Cas adaption module.

11. The production strain bacterial cell of claim 1 , wherein the nucleic acid vector is devoid of a nucleotide sequence encoding one or more of a Cas1, Cas2, Cas4, Cas6, Cas7, and Cas8.

12. The production strain bacterial cell of claim 1 , wherein the second nucleotide sequence encodes one or more of (a)-(g):

(a) Cas11, Cas7, and Cas8a1;

(b) Cas8b1, Cas7, and Cas5;

(c) Cas5, Cas8c, and Cas7;

(d) Cas8U2, Cas7, Cas5, and Cas6;

(e) Cas10d, Cas7, and Cas5;

(f) Cas8e, Cas11, Cas7, Cas5, and Cas6; and

(g) Cas8f, Cas5, Cas7, and Cas6f.

13. The production strain bacterial cell of claim 12 , wherein the Type I Cas3 is a Cas3′ or Cas3″.

14. The production strain bacterial cell of claim 12 , wherein the Type I Cas3 is a Cas3, Cas3′ or Cas3″, and wherein the Type I Cas3 is between the promoter and the second nucleotide sequence.

15. The production strain bacterial cell of claim 14 , wherein the nucleic acid vector is devoid of a nucleotide sequence encoding a further Cas between the promoter and the Type I Cas3.

16. The production strain bacterial cell of claim 12 , wherein the vector comprises the CRISPR array, the CRISPR array is cognate with the Type I Cas3, and wherein:

(a) the CRISPR array is a Type IA array and the nucleic acid vector comprises Cas11, Cas7, and Cas8a1;

(b) the CRISPR array is a Type IB array and the nucleic acid vector comprises Cas8b1, Cas7, and Cas5;

(c) the CRISPR array is a Type IC array and the nucleic acid vector comprises Cas5, Cas8c, and Cas7;

(d) the CRISPR array is a Type IU array and the nucleic acid vector comprises Cas8U2, Cas7, Cas5, and Cas6;

(e) the CRISPR array is a Type ID array and the nucleic acid vector comprises Cas10d, Cas7, and Cas5;

(f) the CRISPR array is a Type IE array and the nucleic acid vector comprises Cas8e, Cas11, Cas7, Cas5, and Cas6; or

(g) the CRISPR array is a Type IF array and the nucleic acid vector comprises Cas8f, Cas5, Cas7, and Cas6f.

17. The production strain bacterial cell of claim 1 , wherein the Type I Cas3 and Cascade are:

(a) Type IA Cas and Cascade proteins;

(b) Type IB Cas and Cascade proteins;

(c) Type IC Cas and Cascade proteins;

(d) Type ID Cas and Cascade proteins;

(e) Type IE Cas and Cascade proteins;

(f) Type IF Cas and Cascade proteins; or

(g) Type IU Cas and Cascade proteins.

18. The production strain bacterial cell of claim 1 , wherein the Type I Cas3 and Cascade are E. coli Cas and Cascade proteins.

19. The production strain bacterial cell of claim 1 , wherein the Type I Cas3 and Cascade are E. coli, C. difficile, P. aeruginosa, K. pneumoniae, P. furiosus , or B. halodurans Cas and Cascade proteins.

20. The production strain bacterial cell of claim 1 , wherein the Type I Cas3 is a Cas3 of a CRISPR/Cas locus of E. coli , and wherein the distance between the Cas3-encoding sequence of the locus and its cognate promoter in E. coli is further than the distance between the Cas3-encoding sequence and the promoter for controlling the expression of Type I Cas3 in the nucleic acid vector.

21. The production strain bacterial cell of claim 1 , wherein the CRISPR array or the gRNA-encoding sequence is under the control of a second promoter that is different from the promoter that controls the expression of the Type I Cas3.

22. The production strain bacterial cell of claim 1 , wherein the nucleic acid vector is a plasmid or phagemid.

23. The production strain bacterial cell of claim 1 , wherein the production strain bacterial cell comprises a nucleotide sequence whose expression is inducible to produce phage coat proteins in the cell of the production strain,

wherein the production strain bacterial cell comprises amplified copies of the nucleic acid vector,

wherein the production strain bacterial cell is capable of packaging the amplified copies of the nucleic acid vector into phage particles or non-self-replicative transduction particles for introducing the amplified copies of the nucleic acid vector into the target host cell.

24. The production strain bacterial cell of claim 23 , wherein the nucleic acid vector is a plasmid or phagemid and the delivery vehicle is a non-replicative transduction particle.

25. The production strain bacterial cell of claim 1 , wherein the second nucleotide sequence is under the control of the same promoter as the first nucleotide sequence.

26. The production strain bacterial cell of claim 1 , wherein the target sequence of the target bacterial host cell is a chromosomal sequence of the target bacterial host cell.

27. The production strain bacterial cell of claim 1 , wherein the production strain bacterial cell is an Escherichia coli ( E. coli ) cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2025
From: MARTINEZ, VIRGINIA; VAZQUEZ-URIBE, RUBEN; TAKOS, ADAM; VAN DER HELM, ERIC
To: SNIPR BIOME APS
Reel/Frame 071131/0506 →
Priority Claims (2)
GB 1816700 · Oct 14, 2018 · national
GB 1817509 · Oct 27, 2018 · national
Continuity (2)
Continuation 16201736 · Nov 27, 2018
Related Publication 20240141365A1 · May 2, 2024
References Cited (400)
US 4626504A · Puhler · 1986 [cited by applicant]
US 5633154A · Schaefer · 1997 [cited by applicant]
US 8241498B2 · Summer · 2012 [cited by applicant]
US 8252576B2 · Campbell · 2012 [cited by applicant]
US 8906682B2 · June · 2014 [cited by applicant]
US 8911993B2 · June · 2014 [cited by applicant]
US 8916381B1 · June · 2014 [cited by applicant]
US 8975071B1 · June · 2015 [cited by applicant]
US 9101584B2 · June · 2015 [cited by applicant]
US 9102760B2 · June · 2015 [cited by applicant]
US 9102761B2 · June · 2015 [cited by applicant]
US 9113616B2 · MacDonald et al. · 2015 [cited by applicant]
US 9328156B2 · June · 2016 [cited by applicant]
US 9464140B2 · June · 2016 [cited by applicant]
US 9481728B2 · June · 2016 [cited by applicant]
US 9499629B2 · June · 2016 [cited by applicant]
US 9518123B2 · June · 2016 [cited by applicant]
US 9540445B2 · June · 2017 [cited by applicant]
US 9701964B2 · Clube · 2017 [cited by applicant]
US 10195273B2 · Clube · 2019 [cited by applicant]
US 10300138B2 · Clube · 2019 [cited by applicant]
US 10300139B2 · Clube · 2019 [cited by applicant]
US 10363308B2 · Clube et al. · 2019 [cited by applicant]
US 10463049B2 · Clube · 2019 [cited by applicant]
US 10506812B2 · Clube · 2019 [cited by applicant]
US 10524477B2 · Clube · 2020 [cited by applicant]
US 10561148B2 · Clube · 2020 [cited by applicant]
US 10582712B2 · Clube · 2020 [cited by applicant]
US 10596255B2 · Clube · 2020 [cited by applicant]
US 10603379B2 · Clube et al. · 2020 [cited by applicant]
US 10624349B2 · Clube · 2020 [cited by applicant]
US 10751427B2 · Clube · 2020 [cited by applicant]
US 10760075B2 · Sommer et al. · 2020 [cited by applicant]
US 10765740B2 · Clube · 2020 [cited by applicant]
US 10920222B2 · Sommer et al. · 2021 [cited by applicant]
US 10953090B2 · Clube et al. · 2021 [cited by applicant]
US 11141481B2 · Clube · 2021 [cited by applicant]
US 11147830B2 · Clube · 2021 [cited by applicant]
US 11291723B2 · Clube · 2022 [cited by applicant]
US 11351252B2 · Clube · 2022 [cited by applicant]
US 11400110B2 · Clube · 2022 [cited by applicant]
US 11421227B2 · Sommer et al. · 2022 [cited by applicant]
US 11471530B2 · Clube · 2022 [cited by applicant]
US 11471531B2 · Clube et al. · 2022 [cited by applicant]
US 11485973B2 · Sommer et al. · 2022 [cited by applicant]
US 11517582B2 · Clube et al. · 2022 [cited by applicant]
US 11547716B2 · Clube · 2023 [cited by applicant]
US 11578333B2 · Martinez et al. · 2023 [cited by applicant]
US 11612617B2 · Clube · 2023 [cited by applicant]
US 11629350B2 · Martinez et al. · 2023 [cited by applicant]
US 11642363B2 · Clube et al. · 2023 [cited by applicant]
US 11643653B2 · Sommer et al. · 2023 [cited by applicant]
US 11788085B2 · Sommer et al. · 2023 [cited by applicant]
US 11851663B2 · Martinez · 2023 [cited by applicant]
US 11891629B2 · Clube · 2024 [cited by applicant]
US 11931426B2 · Clube · 2024 [cited by applicant]
US 12076375B2 · Haaber et al. · 2024 [cited by applicant]
US 12226430B2 · Clube et al. · 2025 [cited by applicant]
US 20040096974A1 · Herron · 2004 [cited by applicant]
US 20050118719A1 · Schmidt · 2005 [cited by applicant]
US 20110136688A1 · Scholl · 2011 [cited by applicant]
US 20130109053A1 · Macdonald · 2013 [cited by applicant]
US 20130287748A1 · June · 2013 [cited by applicant]
US 20130288368A1 · June · 2013 [cited by applicant]
US 20130309258A1 · June · 2013 [cited by applicant]
US 20140106449A1 · June · 2014 [cited by applicant]
US 20140107092A1 · Meyerson · 2014 [cited by applicant]
US 20140234972A1 · Zhang · 2014 [cited by applicant]
US 20140370017A1 · June · 2014 [cited by applicant]
US 20150050699A1 · Siksnys · 2015 [cited by applicant]
US 20150050729A1 · June · 2015 [cited by applicant]
US 20150064138A1 · Lu · 2015 [cited by applicant]
US 20150093822A1 · June · 2015 [cited by applicant]
US 20150099299A1 · June · 2015 [cited by applicant]
US 20150118202A1 · June · 2015 [cited by applicant]
US 20150125463A1 · Cogswell · 2015 [cited by applicant]
US 20150132419A1 · Arvik · 2015 [cited by applicant]
US 20150139943A1 · Campana · 2015 [cited by applicant]
US 20150140001A1 · Lee · 2015 [cited by applicant]
US 20150290244A1 · June · 2015 [cited by applicant]
US 20160009805A1 · Kowanetz · 2016 [cited by applicant]
US 20160024510A1 · Bikard · 2016 [cited by applicant]
US 20160081314A1 · Thurston · 2016 [cited by applicant]
US 20160115488A1 · Zhang · 2016 [cited by applicant]
US 20160115489A1 · Zhang · 2016 [cited by applicant]
US 20160130355A1 · June · 2016 [cited by applicant]
US 20160159907A1 · June · 2016 [cited by applicant]
US 20160160186A1 · Parsley · 2016 [cited by applicant]
US 20160168594A1 · Zhang · 2016 [cited by examiner]
US 20160194404A1 · June · 2016 [cited by applicant]
US 20160208012A1 · June · 2016 [cited by applicant]
US 20160324938A1 · Bikard · 2016 [cited by applicant]
US 20160333348A1 · Clube · 2016 [cited by applicant]
US 20160345578A1 · Barrangou · 2016 [cited by applicant]
US 20160347836A1 · Grosso · 2016 [cited by applicant]
US 20160354416A1 · Gajewski · 2016 [cited by applicant]
US 20170022499A1 · Lu · 2017 [cited by applicant]
US 20170173085A1 · Kovarik · 2017 [cited by applicant]
US 20170173086A1 · Boyle et al. · 2017 [cited by applicant]
US 20170175142A1 · Zhang · 2017 [cited by applicant]
US 20170196225A1 · Clube · 2017 [cited by applicant]
US 20170233708A1 · Liu · 2017 [cited by examiner]
US 20170246221A1 · Clube · 2017 [cited by applicant]
US 20170304443A1 · Lebwohl · 2017 [cited by applicant]
US 20170327582A1 · Bissonnette · 2017 [cited by applicant]
US 20170340733A1 · Cao · 2017 [cited by applicant]
US 20180015131A1 · Gajewski · 2018 [cited by applicant]
US 20180055852A1 · Kutok · 2018 [cited by applicant]
US 20180064114A1 · Clube · 2018 [cited by applicant]
US 20180064115A1 · Clube · 2018 [cited by applicant]
US 20180070594A1 · Clube · 2018 [cited by applicant]
US 20180084785A1 · Clube · 2018 [cited by applicant]
US 20180084786A1 · Clube · 2018 [cited by applicant]
US 20180140698A1 · Clube · 2018 [cited by applicant]
US 20180146681A1 · Clube · 2018 [cited by applicant]
US 20180155729A1 · Beisel · 2018 [cited by applicant]
US 20180179547A1 · Zhang · 2018 [cited by applicant]
US 20180200342A1 · Bikard · 2018 [cited by applicant]
US 20180273940A1 · Sommer · 2018 [cited by applicant]
US 20180303934A1 · Clube · 2018 [cited by applicant]
US 20180305714A1 · Maresca et al. · 2018 [cited by applicant]
US 20180326057A1 · Clube et al. · 2018 [cited by applicant]
US 20180326093A1 · Clube · 2018 [cited by applicant]
US 20190133135A1 · Clube · 2019 [cited by applicant]
US 20190134194A1 · Clube · 2019 [cited by applicant]
US 20190160120A1 · Haaber · 2019 [cited by applicant]
US 20190230936A1 · Clube · 2019 [cited by applicant]
US 20190240325A1 · Clube · 2019 [cited by applicant]
US 20190240326A1 · Clube · 2019 [cited by applicant]
US 20190321468A1 · Clube · 2019 [cited by applicant]
US 20190321469A1 · Clube · 2019 [cited by applicant]
US 20190321470A1 · Clube · 2019 [cited by applicant]
US 20190367947A1 · Lopes Ferreira et al. · 2019 [cited by applicant]
US 20200030444A1 · Clube · 2020 [cited by applicant]
US 20200068901A1 · Clube · 2020 [cited by applicant]
US 20200077663A1 · Clube · 2020 [cited by applicant]
US 20200085066A1 · Clube · 2020 [cited by applicant]
US 20200087660A1 · Sommer et al. · 2020 [cited by applicant]
US 20200102551A1 · Barrangou · 2020 [cited by examiner]
US 20200115716A1 · Martinez · 2020 [cited by applicant]
US 20200121787A1 · Clube · 2020 [cited by applicant]
US 20200128832A1 · Clube · 2020 [cited by applicant]
US 20200164070A1 · Clube · 2020 [cited by applicant]
US 20200205416A1 · Clube · 2020 [cited by applicant]
US 20200254035A1 · Haaber · 2020 [cited by applicant]
US 20200267992A1 · Clube · 2020 [cited by applicant]
US 20200337313A1 · Clube · 2020 [cited by applicant]
US 20200390886A1 · Clube · 2020 [cited by applicant]
US 20210009996A1 · Sommer et al. · 2021 [cited by applicant]
US 20210060180A1 · Clube · 2021 [cited by applicant]
US 20210113689A1 · Clube · 2021 [cited by applicant]
US 20210147827A1 · Clube · 2021 [cited by applicant]
US 20210147857A1 · Clube · 2021 [cited by applicant]
US 20210163960A1 · Martinez et al. · 2021 [cited by applicant]
US 20210189406A1 · Martinez et al. · 2021 [cited by applicant]
US 20210198665A1 · Sommer et al. · 2021 [cited by applicant]
US 20210230559A1 · Clube · 2021 [cited by applicant]
US 20210283167A1 · Clube · 2021 [cited by applicant]
US 20210290654A1 · Clube · 2021 [cited by applicant]
US 20210386773A1 · Clube · 2021 [cited by applicant]
US 20220162270A1 · Szabolcs · 2022 [cited by applicant]
US 20220233575A1 · Clube et al. · 2022 [cited by applicant]
US 20220241318A1 · Clube et al. · 2022 [cited by applicant]
US 20220259588A1 · Sommer et al. · 2022 [cited by applicant]
US 20220273696A1 · Clube · 2022 [cited by applicant]
US 20220275380A1 · Porse · 2022 [cited by applicant]
US 20220282245A1 · Sommer et al. · 2022 [cited by applicant]
US 20220290133A1 · Sommer et al. · 2022 [cited by applicant]
US 20220362280A1 · Clube · 2022 [cited by applicant]
US 20220387559A1 · Haaber et al. · 2022 [cited by applicant]
US 20230193241A1 · Clube et al. · 2023 [cited by applicant]
US 20230248822A1 · Clube · 2023 [cited by applicant]
US 20230330167A1 · Haaber · 2023 [cited by applicant]
US 20230364268A1 · Clube · 2023 [cited by applicant]
US 20240082289A1 · Clube et al. · 2024 [cited by applicant]
US 20240384279A1 · Munck et al. · 2024 [cited by applicant]
US 20250002942A1 · Semsey et al. · 2025 [cited by applicant]
US 20250043291A1 · Le Miere et al. · 2025 [cited by applicant]
CN 105555948A · 2016 [cited by applicant]
CN 107557378A · 2018 [cited by applicant]
EP 2840140A1 · 2015 [cited by applicant]
EP 3132035B8 · 2020 [cited by applicant]
EP 3132036B8 · 2020 [cited by applicant]
EP 3630975A1 · 2020 [cited by applicant]
EP 3633032A2 · 2020 [cited by applicant]
EP 3634442A1 · 2020 [cited by applicant]
EP 3634473A1 · 2020 [cited by applicant]
RU 2531343C2 · 2014 [cited by applicant]
WO 2005046579A2 · 2005 [cited by applicant]
WO 2005046579A3 · 2005 [cited by applicant]
WO 2007025097A2 · 2007 [cited by applicant]
WO 2008108989A2 · 2008 [cited by applicant]
WO 2010011961A2 · 2010 [cited by applicant]
WO 2010075424A2 · 2010 [cited by applicant]
WO 2012079000A1 · 2012 [cited by applicant]
WO 2012079000A4 · 2012 [cited by applicant]
WO 2012164565A1 · 2012 [cited by applicant]
WO 2013063361A1 · 2013 [cited by applicant]
WO 2013176772A1 · 2013 [cited by applicant]
WO 2014012001A2 · 2014 [cited by applicant]
WO 2014018423A2 · 2014 [cited by applicant]
WO 2014124226A1 · 2014 [cited by applicant]
WO 2015034872A2 · 2015 [cited by applicant]
WO 2014012001A3 · 2015 [cited by applicant]
WO 2015058018A1 · 2015 [cited by applicant]
WO 2015069682A2 · 2015 [cited by applicant]
WO 2015071474A2 · 2015 [cited by applicant]
WO 2015088643A1 · 2015 [cited by applicant]
WO 2015089419A2 · 2015 [cited by applicant]
WO 2015089419A3 · 2015 [cited by applicant]
WO 2015136541A2 · 2015 [cited by applicant]
WO 2015148680A1 · 2015 [cited by applicant]
WO 2015155686A2 · 2015 [cited by applicant]
WO 2015159068A1 · 2015 [cited by applicant]
WO 2015159086A1 · 2015 [cited by applicant]
WO 2015159087A1 · 2015 [cited by applicant]
WO 2015136541A3 · 2015 [cited by applicant]
WO 2016033088A1 · 2016 [cited by applicant]
WO 2016044745A1 · 2016 [cited by applicant]
WO 2016063263A2 · 2016 [cited by applicant]
WO 2016177682A1 · 2016 [cited by applicant]
WO 2016196361A1 · 2016 [cited by applicant]
WO 2016196605A1 · 2016 [cited by applicant]
WO 2016205276A1 · 2016 [cited by applicant]
WO 2017029485A1 · 2017 [cited by applicant]
WO 2017042347A1 · 2017 [cited by applicant]
WO 2017058751A1 · 2017 [cited by applicant]
WO 2017112620A1 · 2017 [cited by applicant]
WO 2017118598A1 · 2017 [cited by applicant]
WO 2018064165A2 · 2018 [cited by applicant]
WO 2018069474A1 · 2018 [cited by applicant]
WO 2018081502A1 · 2018 [cited by applicant]
WO 2018141907A1 · 2018 [cited by applicant]
WO 2018217351A1 · 2018 [cited by applicant]
WO 2018217981A1 · 2018 [cited by applicant]
WO 2018222969A1 · 2018 [cited by applicant]
WO 2018226853A1 · 2018 [cited by applicant]
WO 2019002207A1 · 2019 [cited by applicant]
WO 2019002218A2 · 2019 [cited by applicant]
WO 2020072248A1 · 2020 [cited by applicant]
WO 2020072250A1 · 2020 [cited by applicant]
WO 2020072253A1 · 2020 [cited by applicant]
WO 2020072254A1 · 2020 [cited by applicant]
WO 2022063986A2 · 2022 [cited by applicant]
WO 2024184403A2 · 2024 [cited by applicant]
Leon (Leon et al. How bacteria control the CRISPR-Cas arsenal. Current Opinion in Microbiology 2018, 42:87-95) (Year: 2018). [cited by examiner]
Vercoe (Vercoe et al. Cytotoxic Chromosomal Targeting by CRISPR/Cas Systems Can Reshape Bacterial Genomes and Expel or Remodel Pathogenicity Islands. 2013 PLOS Genetics; vol. 9 | Issue 4 | e1003454) (Year: 2013). [cited by examiner]
Makarova et. al. An updated evolutionary classification of CRISPR-Cas systems. .2015 Nature Rev. Microbial., 13:722-736 (Year: 2015). [cited by examiner]
Maikova et. al. New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System 2018 Frontiers In Microbiology, vol. 9, article 1740 (Year: 2018). [cited by examiner]
Yao (Yao et al. CRISPR-Cas9/Cas12a biotechnology and application in bacteria. vol. 3, Issue 3, Sep. 2018, pp. 135-149) (Year: 2018). [cited by examiner]
Anderson catalog (retrieved from <https://parts.igem.orc/Promoters/Catalog/Anderson>; 2014 from Wayback machine search (Year: 2014). [cited by examiner]
Lim (Lim et al. Fundamental relationship between operon organization and gene expression. 2011. PNAS vol. 108, No. 26, 10626-10631) (Year: 2011). [cited by examiner]
Aklujkar et al. (2010) “Interference With Histidyl-tRNA Synthetase By a CRISPR Spacer Sequence As a Factor In The Evolution Of Pelobacter Carbinolicus,” BMC Evolutionary Biology 10:203, 15 pages. [cited by applicant]
American Lung Association (2019). “Preventing COPD,” retrieved from https://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/symptoms-causes-risk-factors/preventing-copd.html, last visited Aug. 5, 2019, 1 … [cited by applicant]
Anderson Catalog, retrieved from https://parts.igem.org/Promoters/Catalog/Anderson lasted visited Nov. 29, 2018, 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23100, (Aug. 4, 2006), 3 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23101, (Aug. 4, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23102, (Aug. 4, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23103, (Aug. 4, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23104, (Aug. 4, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23105, (Aug. 14, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23106, (Aug. 14, 2006), 5 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23107, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23108, (Aug. 17, 2006), 3 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23109, (Aug. 17, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23110, (Aug. 17, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23111, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23112, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23113, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23114, (Aug. 17, 2006), 2 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23115, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23116, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23117, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23118, (Aug. 17, 2006), 1 pages. [cited by applicant]
Anderson Promotor Collection, BBa_J23119, (Aug. 24, 2006), 3 pages. [cited by applicant]
Ang, Y.L.E. et al. (2015). “Best Practice In The Treatment Of Advanced Squamous Cell Lung Cancer,” Ther. Adv. Respir. Dis. 9(5):224-235. [cited by applicant]
Anonymous (Apr. 2016). “Checkpoint Inhibition: A Promising Immunotherapeutic Approach for Colorectal Cancer,” Oncology, 5(3):1-5, retrieved from http//www.personalizedmedonc.com/publications/prno/april-2016-vol-5-no-3/c… [cited by applicant]
Arnold, I.C. et al. (Apr. 8, 2015, e-pub. Mar. 4, 2015). “Helicobacter Hepaticus Infection In BALB/c Mice Abolishes Subunit-Vaccine-Induced Protection Against M. Tuberculosis,” Vaccine 33(15):1808-1814. [cited by applicant]
Arslan, Z. et al. (May 7, 2013). “RcsB-BglJ-Mediated Activation of Cascade Operon Does Not Induce The Maturation of CRISPR RNAs in [cited by applicant]
Arumugam et al. (May 12, 2011). “Enterotypes of the human gut microbiome,” Nature 473(7346):174-180, 16 pages. [cited by applicant]
Barrangou, R. et al. (Mar. 23, 2007). “CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes,” Science, 315:1709-1712. [cited by applicant]
Barrett, K.J. et al. (1976). “Interactions Between A Satellite Bacteriophage and Its Helper,” J. Mol. Biol. 106:683-707. [cited by applicant]
Beisel, C.L. et al. (2014). “A CRISPR Design For Next-Generation Antimicrobials,” Genome Biology 15:516, 4 pages. [cited by applicant]
Belizario, J.E. et al. (Oct. 6, 2015). “Human Microbiomes and Their Roles In Dysbiosis, Common Diseases, and Novel Therapeutic Approaches,” Frontiers in Microbiology 6(1050):1-16. [cited by applicant]
Bertram, R. et al. (2008). “The Application of Tet Repressor in Prokaryotic Gene Regulation and Expression,” Microbial Biotechnology 1(1):2-16. [cited by applicant]
Bikard, D. et al. (2013, e-pub. Jun. 12, 2013). “Programmable Repression and Activation Of Bacterial Gene Expression Using an Engineered CRISPR-Cas System,” Nucleic Acids Research 41(15):7429-7437. [cited by applicant]
Bikard, D. et al. (2017, e-pub. Sep. 6, 2017). “Using CRISPR-Cas Systems as Antimicrobials,” Current Opinion in Microbiology 37:155-160. [cited by applicant]
Bikard, D. et al. (Aug. 16, 2012). “CRISPR Interference Can Prevent Natural Transformation and Virulence Acquisition during In Vivo Bacterial Infection,” Cell Host & Microbe 12(2):177-186. [cited by applicant]
Bikard, D. et al. (Nov. 2014, e-pub. May 1, 2015). “Development of Sequence-Specific Antimicrobials Based On Programmable CRISPR-Cas Nucleases,” Nature Biotechnology 32(11):1146-1150, 16 pages. [cited by applicant]
Broaders, E. et al. (Jul./Aug. 2013). “Mobile Genetic Elements Of The Human Gastrointestinal Tract,” Gut Microbes 4(4):271-280. [cited by applicant]
Brouns, S.J.J. et al. (Aug. 15, 2008). Supplemental Material for “Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science 321:960-964. [cited by applicant]
Brouns, S.J.J. et al. (Aug. 15, 2008).“Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes,” Science 321:960-964. [cited by applicant]
Bryksin, A. V. et al. (Oct. 8, 2010). “Rational Design Of a Plasmid Origin That Replicates Efficiently In Both Gram-Positive and Gram-Negative Bacteria,” PloS One 5(10):e13244, 9 pages. [cited by applicant]
Bugrysheva, J.V. et al. (Jul. 2011, E-Pub. Apr. 29, 2011). “The Histone-Like Protein Hip Is Essential For Growth Of [cited by applicant]
Chan, B.K. et al. (2013). “Phage Cocktails and the Future of Phage Therapy,” Future Microbiol. 8(6):769-783. [cited by applicant]
Chan, C.T.Y. et al. (Dec. 2015). “‘Deadman’ and ‘Passcode’ Microbial Kill Switches For Bacterial Containment,” Nat. Chem. Biol. 12(2):82-86. [cited by applicant]
Chasteen, L. et al. (2006, e-pub. Nov. 6, 2006). “Eliminating Helper Phage From Phage Display,” Nucleic Acids Research 34(21):e145, 11 pages. [cited by applicant]
Cheadle, E.J. et al. (2012). “Chimeric Antigen Receptors For T-Cell Based Therapy,” Methods Mol. Biol. 907:645-666, 36 pages. [cited by applicant]
Chen, S. et al. (Feb. 2007, e-pub. Dec. 22, 2006). “Characterization of Strong Promoters From an Environmental Flavobacterium himernum Strain by Using a Green Fluorescent Protein-based Reporter System,” Applied and Envi… [cited by applicant]
Christie, G.E. (1990). “Interactions Between Satellite Bacteriophage P4 and Its Helpers,” Annu. Rev. Genet. 24:465-490. [cited by applicant]
Christie, G.E. (2012, e-pub. Nov. 3, 2012). “Pirates Of The Caudovirales,” Virology 434:210-221. [cited by applicant]
Citorik, R.J. et al. (Nov. 2014, e-pub Sep. 21, 2014). “Sequence-Specific Antimicrobials Using Efficiently Delivered RNA-Guided Nucleases,” Nat. Biotechnol. 32(11):1141-1145, 18 pages. [cited by applicant]
Cochrane, K. et al. (2016, e-pub. Nov. 3, 2015). “Complete Genome Sequences and Analysis Of The [cited by applicant]
Coyne, M.J. et al. (2014). “Evidence of Extensive DNA Transfer between [cited by applicant]
De Filippo, C. et al. (August 33 2010). “Impact Of Diet In Shaping Gut Microbiota Revealed By a Comparative Study In Children From Europe and Rural Africa,” Proc. Natl. Acad. Sci. USA 107(33):14691-14696, 6 pages. [cited by applicant]
De Paepe, M. et al. (Mar. 28, 2014). “Bacteriophages: An Underestimated Role In Human and Animal Health?” Frontiers in Cellular and Infection Microbiology 4(39):1-11. [cited by applicant]
Deeks, E.D. (2014, e-pub. Jul. 15, 2014). “Nivolumab: A Review Of Its Use In Patients With Malignant Melanoma,” Drugs 74:1233-1239. [cited by applicant]
Deghorain, M. et al. (Nov. 23, 2012). “The Staphylococci Phages Family: An Overview,” Viruses 4:3316-3335. [cited by applicant]
Dickson, R.P. et al. (Jan./Feb. 2017). “Bacterial Topography of the Healthy Human Lower Respiratory Tract,” American Society for Microbiology 8(1):e02287-6, 12 pages. [cited by applicant]
Diez-Villasenor, C. et al. (May 2013). “CRISPR-Spacer Integration Reporter Plasmids Reveal Distinct Genuine Acquisition Specificities Among CROSPR-Cas 1-E Variants of [cited by applicant]
Dutilh, B.E. et al. (Jul. 24, 2014). “A Highly Abundant Bacteriophage Discovered In The Unknown Sequences Of Human Faecal Metagenomes,” Nature Communications 5(4498):1-11. [cited by applicant]
Edgar et al. (Dec. 2010). “The [cited by applicant]
Ex Parte Re-Exam, mailed Dec. 10, 2018, for U.S. Appl. No. 90/014,184, filed Aug. 10, 2018, for Reexamination U.S. Pat. No. 9,701,964 102 pages. [cited by applicant]
Extended European Search Report, dated Mar. 6, 2020, for European Patent Application No. 190202999.99, 10 pages. [cited by applicant]
Extended European Search Report, dated May 10, 2021, for European Patent Application No. 20217137.7, 5 pages. [cited by applicant]
Final Office Action, mailed Jul. 15, 2021, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 32 pages. [cited by applicant]
Final Office Action, mailed Mar. 14, 2022, for U.S. Appl. No. 17/195,157, filed Mar. 8, 2021, 23 pages. [cited by applicant]
Final Office Action, mailed May 29, 2020, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 10 pages. [cited by applicant]
Final Office Action, mailed Nov. 14, 2022, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 88 pages. [cited by applicant]
Final Office Action, mailed Sep. 28, 2021, for U.S. Appl. No. 17/166,941, filed Feb. 3, 2021, 22 pages. [cited by applicant]
Foca, A. et al. (2015, e-pub. Apr. 7, 2015). Gut Inflammation and Immunity: What Is The Role Of The Human Gut Virome? Mediators of Inflammation 2015(326032):1-7. [cited by applicant]
Galperin, M.Y. (Dec. 2013). “Genome Diversity of Spore-Forming Firmicutes,” Microbiology Spectrum 1(2):TBS-0015-2012, 27 pages. [cited by applicant]
Garon, E.B. et al. (Oct. 2015). “Current Perspectives In Immunotherapy For Non-Small Cell Lung Cancer,” Seminars In Oncology 42(5 Supp. 2):S11-S18. [cited by applicant]
Garrett W.S. et al. (Oct. 5, 2007). “Communicable Ulcerative Colitis Induced By T-Bet Deficiency In The Innate Immune System,” Cell 131(1):33-45, 23 pages. [cited by applicant]
Golubovskaya, V. et al. (Mar. 15, 2016). “Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy,” Cancers 8(36), 12 pages. [cited by applicant]
Gomaa et al. (Jan. 28, 2014). “Programmable Removal Of Bacterial Strains By Use Of Genome-Targeting CRISPR-Cas Systems,” mBio, 5(1):e000928-13, pp. 1-9. [cited by applicant]
Gomaa, A.A. et al. (Jan./Feb. 2014). Supplemental Material to “Programmable Removal of Bacterial Strains by Use of GenomeTargeting CRISPR-Cas Systems,” American Society for Microbiology 5(1):1-9. [cited by applicant]
Gudbergsdottir, S. et al. (2011, e-pub. Nov. 18, 2010). “Dynamic Properties of The Sulfolobus CRISPR/Cas and CRISPR/Cmr Systems When Challenged With Vector-Borne Viral and Plasmid Genes and Protospacers,” Molecular Micr… [cited by applicant]
Guedan, S. et al. (Aug. 14, 2014). “ICOS-Based Chimeric Antigen Receptors Program Bipolar TH17/TH1 Cells,” Blood 124(7):1070-1080. [cited by applicant]
Hargreaves, K.R. et al. (Aug. 26, 2014). “Abundant and Diverse Clustered Regularly Interspaced Short Palindromic Repeat Spacers in Clostridium difficile Strains and Prophages Target Multiple Phage Types within This Path… [cited by applicant]
Harrington, L.E. (Nov. 2005, e-pub. Oct. 2, 2005). “Interleukin 17-producing CD4+ Effector T Cells Develop Via a Lineage Distinct From The T Helper Type 1 and 2 Lineages,” Nat. Immunol. 6(11):1123-1132. [cited by applicant]
Hooper, L.V. et al. (Jun. 8, 2012). “Interactions Between The Microbiota and The Immune System,” Science 336 (6086):1268-1273, 16 pages. [cited by applicant]
Horvath, P. et al. (2008, e-pub. Dec. 7, 2007). “Diversity, Activity, and Evolution Of CRISPR Loci In [cited by applicant]
Huddleston, J.R. (Jun. 20, 2014). “Horizontal Gene Transfer In The Human Gastrointestinal Tract: Potential Spread Of Antibiotic Resistance Genes,” Infection and Drug Resistance 7:167-176. [cited by applicant]
International Search Report and The Written Opinion of the International Searching Authority for PCT/EP2018/066954, mailed Oct. 23, 2018, filed Jun. 25, 2018, 14 pages. [cited by applicant]
International Search Report for PCT/EP2016/059803, mailed Jun. 30, 2016, filed May 3, 2016, 6 pages. [cited by applicant]
International Search Report for PCT/EP2018/082053, mailed Mar. 14, 2019, filed Nov. 21, 2018, 9 pages. [cited by applicant]
International Search Report for PCT/EP2019/077760, mailed Mar. 6, 2020, filed Oct. 14, 2019, 15 pages. [cited by applicant]
Ivanov, I.I. et al. (May 2010). “Segmented Filamentous Bacteria Take The Stage,” Muscosal Immunol. 3(3):209-212, 7 pages. [cited by applicant]
Jiang, W. et al. (Nov. 2013). “Demonstration Of CRISPR/Cas9/sgRNA-Mediated Targeted Gene Modification In [cited by applicant]
Jin, Y. et al. (2019, e-pub. Apr. 23, 2019). “The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC,” Journal of Thoracic Oncology… [cited by applicant]
Jinek et al. (Aug. 17, 2012). “A Programmable Dual-RNA-Guided DNA Endonuclease In Adaptive Bacterial Immunity,” Science 337(6096):816-821. [cited by applicant]
Kanhere, A. et al. (2005). Structural Properties of Promoters: Similarities and Differences Between Prokaryotes and Eukaryotes Nucleic Acids Research 33(10):3165-3175. [cited by applicant]
Khoja, L. et al. (2015). “Pembrolizumab,” Journal For ImmunoTherapy Of Cancer 3(36):1-13. [cited by applicant]
Kim, J.-S. (2016). “CRISPR/Cas9-Mediated Re-Sensitization of Antibiotic-Resistant [cited by applicant]
Kochenderfer, J.N. et al. (Sep. 2009). “Construction and Pre-clinical Evaluation Of An Anti-CD19 Chimeric Antigen Receptor,” J. Immunother. 32(7):689-702, 26 pages. [cited by applicant]
Kosiewicz, M.M. et al. (2014, e-pub. Mar. 26, 2014). “Relationship Between Gut Microbiota and Development of T Cell Associated Disease,” FEBS Lett. 588:4195-4206. [cited by applicant]
Krom, R.J. et al. (Jul. 5, 2015). “Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies,” Nano Letters 15(7):4808-4813. [cited by applicant]
Leon, L.M. et al. (Apr. 2018). “How Bacteria Control the CRISPR-Cas Arsenal,” Current Opinion in Microbiology 42:87-95, 17 pages. [cited by applicant]
Li, Q. et al. (2016, e-pub. May 23, 2016). “CRISPR-Based Genome Editing and Expression Control Systems in Clostridium acetobutyloum and Clostridium beijerinckii,” Biotechnology Journal 11:961-972. [cited by applicant]
Lim, H.N. et al. (Jun. 28, 2011, e-pub. Jun. 13, 2011). “Fundamental Relationship Between Operon Organization and Gene Expression,” PNAS 108(26):10626-10631. [cited by applicant]
Lopez-Sanchez, M.-J. et al. (2012, e-pub. Jul. 27, 2012). “The Highly Dynamic CRISPR1 System Of [cited by applicant]
Ludwig, W. et al. (1985). “The Phylogenetic Position Of [cited by applicant]
Luo, M.L. et al. (2015, e-pub. Oct. 17, 2014). “Repurposing Endogenous Type I CRISPR-Cas Systems For Programmable Gene Repression,” Nucleic Acids Research 43(1):674-681. [cited by applicant]
Lutz, R. et al. (1997). “Independent and Tight Regulation of Transcriptional Units in [cited by applicant]
López, P. et al. (Apr. 5, 2016). “Th17 Responses and Natural IgM Antibodies Are Related To Gut Microbiota Composition In Systemic Lupus Erythematosus Patients,” Sci. Rep. 6:24072, 12 pages. [cited by applicant]
Magee, M.S. et al. (Nov. 2014). “Challenges To Chimeric Antigen Receptor (CAR)-T Cell Therapy For Cancer,” Discov. Med. 18(100):265-271, 6 pages. [cited by applicant]
Mahoney, K.M. et al. (2015). “The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade In Melanoma,” Clinical Therapeutics 37(4):764-782. [cited by applicant]
Maikova, A. et al. (Jul. 31, 2018), “New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System,” Frontiers In Microbiology 9(1740):1-8. [cited by applicant]
Majsec, K. et al. (2016). “Cas3 Is a Limiting Factor for CRISPR-Cas Immunity in [cited by applicant]
Makarova, K.S. et al. (2015). “Annotation and Classification of CRISPR-Cas Systems,” Methods Mol. Biol. 1311:47-75, 27 pages. [cited by applicant]
Makarova, K.S. et al. (Feb. 27, 2017). “SnapShot: Class 1 CRISPR-Cas Systems,” Cell 168(5):946, 2 pages. [cited by applicant]
Makarova, K.S. et al. (Nov. 2015, e-pub.May 11, 2017). “An Updated Evolutionary Classification of CRISPR—Cas Systems,” Nature Rev. Microbiol. 13(11):722-736, 31 pages. [cited by applicant]
Mancha-Agresti, P. et al. (Mar. 2017). “A New Broad Range Plasmid for DNA Delivery in Eukaryotic Cells Using Lactic Acid Bacteria: In Vitro and In Vivo Assays,” Molecular Therapy: Methods & Clinical Development 4:83-91. [cited by applicant]
Manica, A. et al. (2011, e-pub. Mar. 8, 2011). “In vivo Activity Of CRISPR-Mediated Virus Defence In a Hyperthermophilic Archaeon,” Molecular Microbiology 80(2):481-491. [cited by applicant]
Marraffini, L.A. et al. (Dec. 19, 2008, e-pub. Jun. 12, 2009) “CRISPR Interference Limits Horizontal Gene Transfer In Staphylococci By Targeting DNA,” Science 322(5909):1843-1845, 7 pages. [cited by applicant]
Mayo Clinic (2019). “Pulmonary Embolism,” retrieved from https://www.nnayoclinic.org/diseases-conditions/pulnnonary-ennbolisnn/synnptonns-causes/syc-20354647, last visited Aug. 5, 2019, 8 pages. [cited by applicant]
Mayo Clinic (2020). “Infectious Diseases,” retrieved from https://www.nnayoclinic.org/diseases-conditions/infectious-diseases/diagnosis-treatnnent/drc-20351179, last visited Jan. 17, 2020, 5 pages. [cited by applicant]
Mayo Clinic (2020). “Malaria,” retrieved from https://www.nnayoclinic.org/diseases-conditions/nnalaria/diagnosis-treatnnent/drc-20351190, last visited Jan. 17, 2020, 3 pages. [cited by applicant]
Mayo Clinic (2020). “Sexually Transmitted Diseases (STDs),” retrieved from https://www.nnayoclinic.org/diseases-conditions/sexually-transnnitted-diseases-stds/diagnosis-treatnnent/drc-20351246, last visited Jan. 17, 202… [cited by applicant]
Medina-Aparicio, L. et al. (May 2011, e-pub. Mar. 11, 2011). “The CRI SPR/Cas Immune System Is an Operon Regulated by LeuO, H-NS, and Leucine-Responsive Regulatory Protein in [cited by applicant]
Mercenier, A. (1990). “Molecular Genetics Of [cited by applicant]
Mick, E. et al. (May 2013). “Holding a Grudge: Persisting Anti-Phage CRISPR Immunity In Multiple Human Gut Microbiomes,” RNA Biology 10(5).900-906. [cited by applicant]
Mills, S. et al. (Jan./Feb. 2013). “Movers and Shakers: Influence Of Bacteriophages In Shaping The Mammalian Gut Microbiota,” Gut Microbes 4(1):4-16. [cited by applicant]
Moon, B.Y. et al. (Mar. 8, 2016). “Mobilization of Genomic Islands of [cited by applicant]
Mutalik, V.K. et al. (Apr. 2013, e-pub. Mar. 10, 2013) “Precise and Reliable Gene Expression Via Standard Transcription and Translation Initiation Elements,” Nat. Methods 10(4):354-360. [cited by applicant]
Nakade, S. et al. (2017, e-pub. Jan. 31, 2017). “Cas9, Cpf1 and C2c1/2/3—What's Next?” Bioengineered 8(3):265-273. [cited by applicant]
Nakamura, S. et al. (Nov. 2008). “Metagenomic Diagnosis Of Bacterial Infections,” Emerging Infectious Diseases 14(11):1784-1786. [cited by applicant]
Nale, J.Y. et al. (2012). “Diverse Temperate Bacteriophage Carriage In Clostridium Difficile 027 Strains,” PloS One 7(5):e37263, 9 pages. [cited by applicant]
Navarre, W.W. et al. (2007). “Silencing of Xenogeneic DNA by H-NS—Facilitation Of Lateral Gene Transfer In Bacteria By A Defense System That Recognizes Foreign DNA,” Genes & Development 21:1456-1471. [cited by applicant]
Nelson, M.H. et al. (2015). “Harnessing The Microbiome To Enhance Cancer Immunotherapy,” Journal of Immunology Research 2015: Article 368736, 12 pages. [cited by applicant]
Non-Final Office Action, mailed Aug. 20, 2021, for U.S. Appl. No. 17/195,157, filed Mar. 8, 2021, 17 pages. [cited by applicant]
Non-Final Office Action, mailed Jan. 20, 2022, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 91 pages. [cited by applicant]
Non-Final Office Action, mailed Jun. 7, 2023, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 11 pages. [cited by applicant]
Non-Final Office Action, mailed May 25, 2021, for U.S. Appl. No. 17/166,941, filed Feb. 3, 2021, 17 pages. [cited by applicant]
Non-Final Office Action, mailed Nov. 25, 2019, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 8 pages. [cited by applicant]
Non-Final Office Action, mailed Nov. 30, 2020, for U.S. Appl. No. 16/201,736, filed Nov. 27, 2018, 35 pages. [cited by applicant]
Norris, J.S. et al. (2000). “Prokaryotic Gene Therapy To Combat Multidrug Resistant Bacterial Infection,” Gene Therapy 7:723-725. [cited by applicant]
Novick, R. (May 18, 2018). “Reincarnation Of A Staphylococcal Pathogenicity Island As An antibacterial Drone,” 5th World Congress On Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance: Phage Therapy … [cited by applicant]
Nowak, P. et al. (Nov. 28, 2015). “Gut Microbiota Diversity Predicts Immune Status In HIV-1 Infection,” AIDS 29(18):2409-2418. [cited by applicant]
O'Hara, B.J. et al. (Jun. 8, 2017). “A Highly Specific Phage Defense System Is A Conserved Feature Of The Vibrio cholera Mobilome,” PLOS Genetics 13(6):e1006838, 17 pages. [cited by applicant]
Park, A. (Oct. 18, 2011). “A Surprising Link Between Bacteria and Colon Cancer,” Cancer retrieved from http://healthlande.time.com/2011/10/18/a-surprising-link-between-bacteria-and-colon-cancer/, last visited Aug. 27, 2… [cited by applicant]
Park, H. et al. (2005). “A Distinct Lineage Of CD4 T Cells Regulates Tissue Inflammation By Producing Interleukin 17,” Nat. Immunol. 6(11):1133-1141, 24 pages. [cited by applicant]
Patterson, A.G. et al. (2017, e-pub. Mar. 27, 2017). “Regulation of CRISPR-Cas Adaptive Immune Systems,” Current Opinion in Microbiology 37:1-7. [cited by applicant]
Pawluk, A. et al. (Apr. 15, 2014). “A New Group Of Phage Anti-CRISPR Genes Inhibits The Type I-E CRISPR-Cas System Of Pseudomonas aeruginosa,” mBio. 5(2):e00896. [cited by applicant]
PCT Application No. PCT/EP2018/0071454.(Copy not submitted herewith pursuant to the waiver of 37 C.F.R. 1.98(a) (2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Penades, J.R. et al. (Nov. 2015). “The Phage-Inducible Chromosomal Islands: A Family of Highly Evolved Molecular Parasites,” Annual Review of Virology 2:181-201. [cited by applicant]
Petris, G. et al. (May 22, 2017). “Hit and Go CAS9 Delivered Through a Lentiviral Based Self-Limiting Circuit,” Nature Communications 8:15334, 9 pages. [cited by applicant]
Pires, D.P. et al. (Sep. 2016, e-pub. Jun. 1, 2016), “Genetically Engineered Phages: A Review of Advances Over the Last Decade,” Microbiology and Molecular Biology Reviews 80(3):523-543. [cited by applicant]
Pul, Ü. et al. (2010, e-pub. Feb. 17, 2010). “Identification and Characterization of [cited by applicant]